Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:2-amino-2-deoxy-D-galactopyranose
go back to main search page
Accession:CHEBI:60312 term browser browse the term
Definition:The pyranose form of D-galactosamine.
Synonyms:related_synonym: 2-Amino-2-deoxy-D-galactose;   Chondrosamine;   D-2-Amino-2-deoxygalactose;   D-Chondrosamine;   D-GalN;   D-Galactosamine;   Formula=C6H13NO5;   Galactosamine;   InChI=1S/C6H13NO5/c7-3-5(10)4(9)2(1-8)12-6(3)11/h2-6,8-11H,1,7H2/t2-,3-,4+,5-,6?/m1/s1;   InChIKey=MSWZFWKMSRAUBD-GASJEMHNSA-N;   SMILES=N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O
 xref: Beilstein:2042269;   CAS:7535-00-4;   KEGG:C02262
 xref_mesh: MESH:D005688
 xref: PMID:17456244;   PMID:19913595;   PMID:28709622;   PMID:28752362;   PMID:28821814;   PMID:28921968;   Reaxys:2042269
 cyclic_relationship: is_conjugate_base_of CHEBI:144817


show annotations for term's descendants           Sort by:
 
2-amino-2-deoxy-D-galactopyranose term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Acta2 actin, alpha 2, smooth muscle, aorta increases expression
multiple interactions
ISO Galactosamine results in increased expression of ACTA2 mRNA; Galactosamine results in increased expression of ACTA2 protein
Genistein inhibits the reaction [Galactosamine results in increased expression of ACTA2 mRNA]; Genistein inhibits the reaction [Galactosamine results in increased expression of ACTA2 protein]; glycine propionyl carnitine inhibits the reaction [Galactosamine results in increased expression of ACTA2 protein]
CTD PMID:27836788 PMID:27876602 NCBI chr19:34,240,336...34,255,585
Ensembl chr19:34,241,090...34,255,590
JBrowse link
G Actb actin, beta increases expression ISO Galactosamine results in increased expression of ACTB mRNA CTD PMID:22563491 NCBI chr 5:142,903,115...142,907,976
Ensembl chr 5:142,903,115...142,906,754
JBrowse link
G Afp alpha fetoprotein increases expression ISO Galactosamine results in increased expression of AFP protein CTD PMID:61145 PMID:16965562 NCBI chr 5:90,490,714...90,508,907
Ensembl chr 5:90,490,737...90,508,907
JBrowse link
G Alb albumin multiple interactions
decreases expression
increases expression
ISO [ALB protein co-treated with [Lipopolysaccharides co-treated with Galactosamine]] results in increased expression of IL10 protein; [ALB protein co-treated with [Lipopolysaccharides co-treated with Galactosamine]] results in increased expression of TNF protein
Galactosamine results in decreased expression of ALB protein
Galactosamine results in increased expression of ALB mRNA
CTD PMID:17963606 PMID:18779383 PMID:22310181 NCBI chr 5:90,460,870...90,476,602
Ensembl chr 5:90,460,897...90,476,602
JBrowse link
G Ambp alpha 1 microglobulin/bikunin precursor increases expression ISO Galactosamine results in increased expression of AMBP mRNA CTD PMID:18779383 NCBI chr 4:63,143,275...63,154,172
Ensembl chr 4:63,143,275...63,154,799
JBrowse link
G Apoe apolipoprotein E decreases expression ISO Galactosamine results in decreased expression of APOE protein CTD PMID:6631239 NCBI chr 7:19,696,244...19,701,310
Ensembl chr 7:19,696,109...19,699,188
JBrowse link
G Atf4 activating transcription factor 4 multiple interactions ISO 4-phenylbutyric acid inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of ATF4 mRNA]; 4-phenylbutyric acid inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of ATF4 protein]; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of ATF4 mRNA; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of ATF4 protein CTD PMID:28844859 NCBI chr15:80,255,184...80,257,545
Ensembl chr15:80,255,184...80,257,541
JBrowse link
G Atm ataxia telangiectasia mutated increases expression
multiple interactions
ISO Galactosamine results in increased expression of ATM protein
glycine propionyl carnitine inhibits the reaction [Galactosamine results in increased expression of ATM protein]
CTD PMID:24565947 NCBI chr 9:53,437,122...53,536,828
Ensembl chr 9:53,439,149...53,536,740
JBrowse link
G Bax BCL2-associated X protein multiple interactions
increases expression
EXP
ISO
[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of BAX protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of BAX protein modified form; baicalein inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of BAX protein modified form]; gentiopicroside inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of BAX protein]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of BAX protein modified form]
Galactosamine results in increased expression of BAX mRNA; Galactosamine results in increased expression of BAX protein
[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of BAX mRNA; glycine propionyl carnitine inhibits the reaction [Galactosamine results in increased expression of BAX mRNA]
CTD PMID:20558151 PMID:20850421 PMID:21401295 PMID:22118634 PMID:24565947 NCBI chr 7:45,461,695...45,466,903
Ensembl chr 7:45,461,697...45,466,898
JBrowse link
G Bcl2 B cell leukemia/lymphoma 2 multiple interactions
decreases expression
EXP
ISO
[Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of BCL2 protein; [Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of BCL2 protein modified form; baicalein inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of BCL2 protein modified form]; gentiopicroside inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of BCL2 protein]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of BCL2 protein modified form]
glycine propionyl carnitine inhibits the reaction [Galactosamine results in decreased expression of BCL2 mRNA]; mangiferin inhibits the reaction [Galactosamine results in decreased expression of BCL2 protein]
Galactosamine results in decreased expression of BCL2 mRNA; Galactosamine results in decreased expression of BCL2 protein
CTD PMID:20558151 PMID:20850421 PMID:22118634 PMID:24565947 NCBI chr 1:106,538,176...106,714,290
Ensembl chr 1:106,538,178...106,714,274
JBrowse link
G Bid BH3 interacting domain death agonist multiple interactions ISO [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of BID mRNA; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased cleavage of BID protein CTD PMID:12907702 PMID:21401295 NCBI chr 6:120,893,119...120,917,062
Ensembl chr 6:120,891,930...120,916,853
JBrowse link
G Casp1 caspase 1 multiple interactions EXP [Lipopolysaccharides co-treated with Galactosamine] results in increased activity of CASP1 protein; S-allylcysteine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased activity of CASP1 protein] CTD PMID:32453893 NCBI chr 9:5,298,517...5,307,281
Ensembl chr 9:5,298,508...5,307,290
JBrowse link
G Casp3 caspase 3 multiple interactions
increases expression
increases activity
EXP
ISO
3-Hydroxybutyric Acid promotes the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of CASP3 protein]; [[Galactosamine co-treated with Lipopolysaccharides] results in increased cleavage of and results in increased activity of CASP3 protein] which results in increased cleavage of PARP1 protein; [Galactosamine co-treated with Endotoxins] results in increased activity of CASP3 protein; [Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased cleavage of CASP3 protein; [Galactosamine co-treated with Lipopolysaccharides] results in increased activity of CASP3 protein; [Galactosamine co-treated with Lipopolysaccharides] results in increased cleavage of and results in increased activity of CASP3 protein; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of CASP3 protein modified form; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased activity of CASP3 protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased activity of CASP3 protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of CASP3 protein modified form; [Methylene Chloride co-treated with Biliverdine] inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased activity of CASP3 protein]; [Nitric Oxide Donors results in increased abundance of Nitric Oxide] inhibits the reaction [[TNF protein co-treated with Galactosamine] results in increased activity of CASP3 protein]; [TNF protein co-treated with Galactosamine] results in increased activity of CASP3 protein; baicalein inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of CASP3 protein modified form]; beraprost inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased cleavage of CASP3 protein]; Biliverdine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased activity of CASP3 protein]; cobaltiprotoporphyrin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased activity of CASP3 protein]; cobaltiprotoporphyrin inhibits the reaction [TNF protein promotes the reaction [Galactosamine results in increased activity of CASP3 protein]]; Dithiothreitol inhibits the reaction [Nitric Oxide Donors inhibits the reaction [[TNF protein co-treated with Galactosamine] results in increased activity of CASP3 protein]]; gentiopicroside inhibits the reaction [[[Galactosamine co-treated with Lipopolysaccharides] results in increased cleavage of and results in increased activity of CASP3 protein] which results in increased cleavage of PARP1 protein]; gentiopicroside inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased cleavage of and results in increased activity of CASP3 protein]; gentiopicroside inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of CASP3 protein modified form]; Melatonin inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased activity of CASP3 protein]; Methylene Chloride inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased activity of CASP3 protein]; ONO 1301 inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased cleavage of CASP3 protein]; Rotenone inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased activity of CASP3 protein]; S-allylcysteine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased activity of CASP3 protein]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of CASP3 protein modified form]; TNF protein promotes the reaction [Galactosamine results in increased activity of CASP3 protein]; Ursodeoxycholic Acid analog inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased activity of CASP3 protein]
[Galactosamine co-treated with TNF protein] results in increased activity of CASP3 protein; alpha-Tocopherol inhibits the reaction [Galactosamine results in increased cleavage of and results in increased activity of CASP3 protein]; Galactosamine results in increased cleavage of and results in increased activity of CASP3 protein; Ketoconazole inhibits the reaction [Galactosamine results in increased activity of CASP3 protein]; Rifampin promotes the reaction [Galactosamine results in increased activity of CASP3 protein]
Galactosamine results in increased expression of CASP3 mRNA; Galactosamine results in increased expression of CASP3 protein
2-Acetylaminofluorene inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased cleavage of CASP3 protein]; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of CASP3 mRNA; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased cleavage of CASP3 protein; Alprostadil inhibits the reaction [Galactosamine results in increased cleavage of and results in increased activity of CASP3 protein]; Galactosamine results in increased cleavage of and results in increased activity of CASP3 protein; glycine propionyl carnitine inhibits the reaction [Galactosamine results in increased expression of CASP3 mRNA]; mangiferin inhibits the reaction [Galactosamine results in increased expression of CASP3 protein]
CTD PMID:9388267 PMID:12907702 PMID:14512878 PMID:15486963 PMID:15565661 PMID:15610455 PMID:17602819 PMID:17936189 PMID:20558151 PMID:20850421 PMID:21146893 PMID:21401295 PMID:22023962 PMID:22118634 PMID:22310181 PMID:24565947 PMID:24830863 PMID:26176423 PMID:28887131 PMID:31332890 PMID:32453893 NCBI chr 8:46,617,291...46,639,698
Ensembl chr 8:46,617,291...46,639,689
JBrowse link
G Casp7 caspase 7 multiple interactions EXP [Galactosamine co-treated with Lipopolysaccharides] results in increased activity of CASP7 protein; Ursodeoxycholic Acid analog inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased activity of CASP7 protein] CTD PMID:21146893 NCBI chr19:56,396,833...56,442,348
Ensembl chr19:56,397,129...56,442,344
JBrowse link
G Casp8 caspase 8 multiple interactions EXP 3-Hydroxybutyric Acid promotes the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of CASP8 protein]; [Galactosamine co-treated with Lipopolysaccharides] results in increased activity of CASP8 protein; [Galactosamine co-treated with Lipopolysaccharides] results in increased cleavage of and results in increased activity of CASP8 protein; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of CASP8 protein modified form; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased activity of CASP8 protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of CASP8 protein modified form; baicalein inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of CASP8 protein modified form]; gentiopicroside inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased cleavage of and results in increased activity of CASP8 protein]; gentiopicroside inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of CASP8 protein modified form]; Rotenone inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased activity of CASP8 protein]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of CASP8 protein modified form]; Ursodeoxycholic Acid analog inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased activity of CASP8 protein] CTD PMID:20558151 PMID:20850421 PMID:21146893 PMID:24830863 PMID:31332890 NCBI chr 1:58,795,233...58,847,503
Ensembl chr 1:58,795,374...58,847,503
JBrowse link
G Casp9 caspase 9 multiple interactions
increases expression
EXP
ISO
3-Hydroxybutyric Acid promotes the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of CASP9 protein]; [Galactosamine co-treated with Lipopolysaccharides] results in increased cleavage of and results in increased activity of CASP9 protein; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of CASP9 protein modified form; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased activity of CASP9 protein; gentiopicroside inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased cleavage of and results in increased activity of CASP9 protein]; gentiopicroside inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of CASP9 protein modified form]; Rotenone inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased activity of CASP9 protein]
mangiferin inhibits the reaction [Galactosamine results in increased expression of CASP9 protein]
CTD PMID:20558151 PMID:22118634 PMID:24830863 PMID:31332890 NCBI chr 4:141,793,612...141,815,978
Ensembl chr 4:141,793,612...141,815,976
JBrowse link
G Cat catalase multiple interactions
increases activity
decreases activity
EXP
ISO
6-methyl-2-(phenylethynyl)pyridine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased activity of CAT protein]; [Galactosamine co-treated with Lipopolysaccharides] results in decreased activity of CAT protein; [Lipopolysaccharides co-treated with Galactosamine] results in decreased activity of CAT protein; [Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of CAT protein; Caffeine inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in decreased activity of CAT protein]; Oligopeptides inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in decreased activity of CAT protein]; Plant Extracts inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of CAT protein]
Galactosamine results in increased activity of CAT protein
[Ascorbic Acid co-treated with beta Carotene co-treated with alpha-Tocopherol co-treated with Sodium Selenite] inhibits the reaction [Galactosamine results in increased activity of CAT protein]; glycine propionyl carnitine inhibits the reaction [Galactosamine results in decreased activity of CAT protein]
CTD PMID:19153979 PMID:22154906 PMID:27836788 PMID:30236599 PMID:31022331 PMID:32453893 NCBI chr 2:103,453,904...103,485,153
Ensembl chr 2:103,453,849...103,485,160
JBrowse link
G Ccl2 chemokine (C-C motif) ligand 2 multiple interactions EXP [Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of CCL2 mRNA; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of CCL2 mRNA; [Galactosamine co-treated with Lipopolysaccharides] results in increased secretion of CCL2 protein; ONO 1301 inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of CCL2 mRNA]; Ursodeoxycholic Acid analog inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of CCL2 mRNA]; Ursodeoxycholic Acid analog inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased secretion of CCL2 protein] CTD PMID:21146893 PMID:28887131 NCBI chr11:82,035,577...82,037,452
Ensembl chr11:82,035,571...82,037,453
JBrowse link
G Ccl5 chemokine (C-C motif) ligand 5 multiple interactions EXP [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of CCL5 mRNA; [Galactosamine co-treated with Lipopolysaccharides] results in increased secretion of CCL5 protein; Ursodeoxycholic Acid analog inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of CCL5 mRNA]; Ursodeoxycholic Acid analog inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased secretion of CCL5 protein] CTD PMID:21146893 NCBI chr11:83,525,778...83,530,518
Ensembl chr11:83,525,778...83,530,518
JBrowse link
G Cebpa CCAAT/enhancer binding protein (C/EBP), alpha multiple interactions EXP [Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of CEBPA protein; Indomethacin promotes the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of CEBPA protein]; nimesulide promotes the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of CEBPA protein] CTD PMID:22107987 NCBI chr 7:35,119,293...35,121,928
Ensembl chr 7:35,119,293...35,121,928
JBrowse link
G Cflar CASP8 and FADD-like apoptosis regulator multiple interactions EXP [Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of CFLAR protein; baicalein inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of CFLAR protein]; Silymarin inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of CFLAR protein] CTD PMID:20850421 NCBI chr 1:58,711,311...58,758,884
Ensembl chr 1:58,711,508...58,758,884
JBrowse link
G Chuk conserved helix-loop-helix ubiquitous kinase increases phosphorylation
multiple interactions
ISO Galactosamine results in increased phosphorylation of CHUK protein
mangiferin inhibits the reaction [Galactosamine results in increased phosphorylation of CHUK protein]
CTD PMID:22310181 NCBI chr19:44,073,334...44,107,505
Ensembl chr19:44,073,335...44,107,480
JBrowse link
G Col1a1 collagen, type I, alpha 1 increases expression
multiple interactions
ISO Galactosamine results in increased expression of COL1A1 mRNA
Genistein inhibits the reaction [Galactosamine results in increased expression of COL1A1 mRNA]
CTD PMID:27876602 NCBI chr11:94,936,224...94,953,042
Ensembl chr11:94,936,224...94,953,042
JBrowse link
G Col3a1 collagen, type III, alpha 1 increases expression
multiple interactions
ISO Galactosamine results in increased expression of COL3A1 mRNA
Genistein inhibits the reaction [Galactosamine results in increased expression of COL3A1 mRNA]
CTD PMID:27876602 NCBI chr 1:45,311,538...45,349,706
Ensembl chr 1:45,311,538...45,349,706
JBrowse link
G Cpt1a carnitine palmitoyltransferase 1a, liver multiple interactions
decreases expression
ISO alpha-Tocopherol inhibits the reaction [Galactosamine results in decreased expression of CPT1A mRNA] CTD PMID:17936189 NCBI chr19:3,322,326...3,385,735
Ensembl chr19:3,322,334...3,385,733
JBrowse link
G Cxcl2 chemokine (C-X-C motif) ligand 2 multiple interactions EXP [Galactosamine co-treated with Endotoxins] results in increased expression of CXCL2 mRNA; [Galactosamine co-treated with Endotoxins] results in increased expression of CXCL2 protein CTD PMID:15576625 NCBI chr 5:90,903,899...90,905,938
Ensembl chr 5:90,903,871...90,905,938
JBrowse link
G Cxcl3 chemokine (C-X-C motif) ligand 3 multiple interactions EXP [Galactosamine co-treated with Endotoxins] results in increased expression of CXCL1 mRNA; [Galactosamine co-treated with Endotoxins] results in increased expression of CXCL1 protein CTD PMID:15576625 NCBI chr 5:90,786,101...90,788,093
Ensembl chr 5:90,786,103...90,789,600
JBrowse link
G Cyba cytochrome b-245, alpha polypeptide multiple interactions EXP [Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of CYBA protein; ONO 1301 inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of CYBA protein] CTD PMID:28887131 NCBI chr 8:122,424,771...122,432,940
Ensembl chr 8:122,424,776...122,432,930
JBrowse link
G Cycs cytochrome c, somatic multiple interactions EXP [Galactosamine co-treated with Lipopolysaccharides] results in increased localization of CYCS protein; [Lipopolysaccharides co-treated with Galactosamine] affects the localization of CYCS protein; baicalein inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] affects the localization of CYCS protein]; gentiopicroside inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased localization of CYCS protein] CTD PMID:20558151 PMID:20850421 NCBI chr 6:50,562,563...50,566,569
Ensembl chr 6:50,562,563...50,566,538
JBrowse link
G Cyp1a2 cytochrome P450, family 1, subfamily a, polypeptide 2 decreases expression ISO Galactosamine results in decreased expression of CYP1A2 protein CTD PMID:16208626 NCBI chr 9:57,676,937...57,683,655
Ensembl chr 9:57,676,937...57,683,703
JBrowse link
G Cyp2e1 cytochrome P450, family 2, subfamily e, polypeptide 1 decreases expression ISO Galactosamine results in decreased expression of CYP2E1 protein CTD PMID:16208626 NCBI chr 7:140,763,819...140,774,990
Ensembl chr 7:140,763,739...140,774,987
JBrowse link
G Cyp3a11 cytochrome P450, family 3, subfamily a, polypeptide 11 multiple interactions
decreases expression
ISO alpha-Tocopherol inhibits the reaction [Galactosamine results in decreased expression of CYP3A4 mRNA]; Galactosamine inhibits the reaction [alpha-Tocopherol results in increased expression of CYP3A4 mRNA]; Galactosamine inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA] CTD PMID:17936189 NCBI chr 5:145,854,607...145,879,854
Ensembl chr 5:145,854,426...145,879,964
JBrowse link
G Ddit3 DNA-damage inducible transcript 3 multiple interactions ISO 4-phenylbutyric acid inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of DDIT3 mRNA]; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of DDIT3 mRNA CTD PMID:28844859 NCBI chr10:127,290,793...127,296,291
Ensembl chr10:127,290,774...127,296,288
Ensembl chr10:127,290,774...127,296,288
JBrowse link
G Eif2s1 eukaryotic translation initiation factor 2, subunit 1 alpha multiple interactions ISO 4-phenylbutyric acid affects the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased phosphorylation of EIF2S1 protein]; 4-phenylbutyric acid inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of EIF2S1 mRNA]; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of and results in decreased phosphorylation of EIF2S1 protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of EIF2S1 mRNA CTD PMID:28844859 NCBI chr12:78,862,072...78,887,010
Ensembl chr12:78,861,819...78,887,010
JBrowse link
G Gclm glutamate-cysteine ligase, modifier subunit multiple interactions EXP [Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of GCLM mRNA CTD PMID:28887131 NCBI chr 3:122,245,487...122,267,215
Ensembl chr 3:122,245,557...122,270,732
JBrowse link
G Gpt glutamic pyruvic transaminase, soluble multiple interactions
increases expression
ISO
EXP
4-phenylbutyric acid inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased activity of GPT protein]; [Lipopolysaccharides co-treated with Galactosamine] results in increased activity of GPT protein; Genistein inhibits the reaction [Galactosamine results in increased expression of GPT protein]; glycine propionyl carnitine inhibits the reaction [Galactosamine results in increased expression of GPT protein]
(2-(4-(4-isopropoxybenzyl)-phenylamino) imidazoline) inhibits the reaction [beraprost inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of GPT protein]]; (2-(4-(4-isopropoxybenzyl)-phenylamino) imidazoline) inhibits the reaction [ONO 1301 inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of GPT protein]]; 3-Hydroxybutyric Acid promotes the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of GPT protein]; 6-methyl-2-(phenylethynyl)pyridine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased activity of GPT protein]; [Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of GPT protein; [Galactosamine co-treated with Lipopolysaccharides] promotes the reaction [idelalisib results in increased expression of ALT protein]; [Galactosamine co-treated with Lipopolysaccharides] promotes the reaction [Miransertib results in increased expression of ALT protein]; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased activity of GPT protein; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of GPT protein; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased activity of GPT protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased activity of GPT protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of GPT protein; Acetylcysteine inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of GPT protein]; beraprost inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of GPT protein]; Dextromethorphan inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased activity of GPT protein]; ONO 1301 inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of GPT protein]; Plant Extracts inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of GPT protein]; Rotenone inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased activity of GPT protein]; S-allylcysteine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased activity of GPT protein]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of GPT protein]; stattic inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of GPT protein]
CTD PMID:19153979 PMID:24565947 PMID:24830863 PMID:25620059 PMID:27876602 PMID:28844859 PMID:28887131 PMID:30236599 PMID:30822415 PMID:31332890 PMID:31445927 PMID:32453893 NCBI chr15:76,696,726...76,699,675
Ensembl chr15:76,695,716...76,699,686
JBrowse link
G H3f4 H3.4 histone increases expression ISO Galactosamine results in increased expression of H3F4 mRNA CTD PMID:11779202 NCBI chr11:58,961,711...58,962,273
Ensembl chr11:58,961,812...58,962,222
JBrowse link
G Habp2 hyaluronic acid binding protein 2 increases activity EXP Galactosamine results in increased activity of HABP2 protein CTD PMID:11510480 NCBI chr19:56,287,109...56,320,820
Ensembl chr19:56,287,137...56,320,822
JBrowse link
G Hbegf heparin-binding EGF-like growth factor multiple interactions EXP [Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of HBEGF mRNA; beraprost inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of HBEGF mRNA]; ONO 1301 inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of HBEGF mRNA] CTD PMID:28887131 NCBI chr18:36,504,927...36,515,805
Ensembl chr18:36,504,927...36,515,805
JBrowse link
G Hgf hepatocyte growth factor multiple interactions ISO 4-phenylbutyric acid inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of HGF mRNA]; 4-phenylbutyric acid inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of HGF protein]; [Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of HGF mRNA; [Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of HGF protein CTD PMID:28844859 NCBI chr 5:16,553,495...16,619,439
Ensembl chr 5:16,553,495...16,620,152
JBrowse link
G Hmox1 heme oxygenase 1 multiple interactions
decreases expression
EXP
ISO
Galactosamine inhibits the reaction [cobaltiprotoporphyrin results in increased expression of HMOX1 mRNA]
Galactosamine results in decreased expression of HMOX1 protein
[[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of HMOX1 mRNA] which results in increased chemical synthesis of Bilirubin; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of HMOX1 mRNA; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HMOX1 mRNA; mangiferin inhibits the reaction [Galactosamine results in decreased expression of HMOX1 protein]; resveratrol inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HMOX1 mRNA]
CTD PMID:14512878 PMID:19796704 PMID:21401295 PMID:22310181 NCBI chr 8:75,093,618...75,100,593
Ensembl chr 8:75,093,621...75,100,589
JBrowse link
G Hspa5 heat shock protein 5 multiple interactions ISO 4-phenylbutyric acid inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HSPA5 mRNA]; 4-phenylbutyric acid inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HSPA5 protein]; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HSPA5 mRNA; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HSPA5 protein CTD PMID:28844859 NCBI chr 2:34,772,090...34,776,529
Ensembl chr 2:34,771,970...34,777,547
JBrowse link
G Icam1 intercellular adhesion molecule 1 multiple interactions ISO Galactosamine analog inhibits the reaction [TNF results in increased expression of ICAM1 protein] CTD PMID:16431966 NCBI chr 9:21,015,940...21,028,814
Ensembl chr 9:21,015,985...21,028,817
JBrowse link
G Ifng interferon gamma multiple interactions
increases expression
EXP
ISO
[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IFNG mRNA; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IFNG protein; [Methylene Chloride co-treated with Biliverdine] inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IFNG protein]; cobaltiprotoporphyrin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IFNG mRNA]; cobaltiprotoporphyrin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IFNG protein]
mangiferin inhibits the reaction [Galactosamine results in increased expression of IFNG mRNA]
CTD PMID:15486963 PMID:22310181 NCBI chr10:118,441,046...118,445,894
Ensembl chr10:118,441,046...118,445,892
JBrowse link
G Igfbp1 insulin-like growth factor binding protein 1 increases expression ISO Galactosamine results in increased expression of IGFBP1 mRNA CTD PMID:11779202 NCBI chr11:7,197,787...7,202,546
Ensembl chr11:7,197,782...7,202,546
JBrowse link
G Ikbkb inhibitor of kappaB kinase beta multiple interactions
increases phosphorylation
ISO mangiferin inhibits the reaction [Galactosamine results in increased phosphorylation of IKBKB protein] CTD PMID:22310181 NCBI chr 8:22,659,205...22,706,589
Ensembl chr 8:22,659,212...22,706,589
JBrowse link
G Il10 interleukin 10 multiple interactions
decreases expression
EXP
ISO
[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL10 protein; [Methylene Chloride co-treated with Biliverdine] inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL10 protein]; cobaltiprotoporphyrin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL10 protein]
Galactosamine results in decreased expression of IL10 mRNA
[ALB protein co-treated with [Lipopolysaccharides co-treated with Galactosamine]] results in increased expression of IL10 protein; mangiferin inhibits the reaction [Galactosamine results in decreased expression of IL10 mRNA]
CTD PMID:15486963 PMID:17963606 PMID:22310181 NCBI chr 1:131,019,845...131,024,970
Ensembl chr 1:131,019,845...131,024,974
JBrowse link
G Il12b interleukin 12b multiple interactions
increases expression
EXP
ISO
[LEP gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL12B mRNA; [LEPR gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL12B mRNA
mangiferin inhibits the reaction [Galactosamine results in increased expression of IL12B mRNA]
CTD PMID:19913045 PMID:22310181 NCBI chr11:44,400,063...44,414,677
Ensembl chr11:44,400,063...44,414,033
JBrowse link
G Il18 interleukin 18 increases expression
multiple interactions
EXP
ISO
Galactosamine results in increased expression of IL18 mRNA; Galactosamine results in increased expression of IL18 protein
mangiferin inhibits the reaction [Galactosamine results in increased expression of IL18 mRNA]
[LEP gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL18 mRNA; [LEP gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL18 protein; [LEPR gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL18; [LEPR gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL18 mRNA; [LEPR gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL18 protein; Plant Preparations inhibits the reaction [Galactosamine results in increased expression of IL18 mRNA]; Plant Preparations inhibits the reaction [Galactosamine results in increased expression of IL18 protein]
CTD PMID:19913045 PMID:20102673 PMID:22310181 NCBI chr 9:50,554,700...50,581,841
Ensembl chr 9:50,554,827...50,581,840
JBrowse link
G Il1b interleukin 1 beta multiple interactions
increases expression
ISO
EXP
Genistein inhibits the reaction [Galactosamine results in increased expression of IL1B mRNA]; mangiferin inhibits the reaction [Galactosamine results in increased expression of IL1B mRNA]
2-chloro-5-nitrobenzanilide inhibits the reaction [geraniol inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of IL1B protein]]; [Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of IL1B mRNA; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of IL1B protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL1B protein; geraniol inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of IL1B protein]; ONO 1301 inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of IL1B mRNA]; S-allylcysteine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL1B protein]
CTD PMID:15135310 PMID:22310181 PMID:25620059 PMID:28887131 PMID:30550845 PMID:32453893 NCBI chr 2:129,364,569...129,371,164
Ensembl chr 2:129,364,570...129,371,139
JBrowse link
G Il6 interleukin 6 multiple interactions
increases expression
EXP
ISO
3-Hydroxybutyric Acid promotes the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of IL6 protein]; [Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of IL6 mRNA; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of IL6 mRNA; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of IL6 protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL6 protein; [Methylene Chloride co-treated with Biliverdine] inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL6 protein]; cobaltiprotoporphyrin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL6 protein]; Rotenone inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of IL6 mRNA]; Rotenone inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of IL6 protein]; S-allylcysteine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL6 protein]
Galactosamine results in increased expression of IL6 mRNA
glycine propionyl carnitine inhibits the reaction [Galactosamine results in increased expression of IL6 mRNA]; mangiferin inhibits the reaction [Galactosamine results in increased expression of IL6 mRNA]
CTD PMID:15135310 PMID:15486963 PMID:22310181 PMID:24830863 PMID:27836788 PMID:28887131 PMID:31332890 PMID:32453893 NCBI chr 5:30,013,114...30,019,975
Ensembl chr 5:30,013,114...30,019,981
JBrowse link
G Irak1 interleukin-1 receptor-associated kinase 1 multiple interactions EXP [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] promotes the reaction [TRAF6 protein binds to IRAK1 protein]; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased expression of IRAK1 protein; Glycyrrhetinic Acid inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] promotes the reaction [TRAF6 protein binds to IRAK1 protein]] CTD PMID:28213090 NCBI chr  X:74,013,914...74,023,921
Ensembl chr  X:74,013,914...74,023,918
JBrowse link
G Lcat lecithin cholesterol acyltransferase decreases activity ISO Galactosamine results in decreased activity of LCAT protein CTD PMID:6631239 NCBI chr 8:105,939,551...105,943,402
Ensembl chr 8:105,939,551...105,943,382
JBrowse link
G Lep leptin multiple interactions
increases response to substance
EXP [LEP gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL12B mRNA; [LEP gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL18 mRNA; [LEP gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL18 protein; [LEP gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of SPP1 protein; Galactosamine promotes the reaction [LEP gene mutant form results in increased expression of SPP1 mRNA]; Galactosamine promotes the reaction [LEP gene mutant form results in increased expression of SPP1 protein]; SPP1 promotes the reaction [LEP gene mutant form results in increased susceptibility to Galactosamine] CTD PMID:19913045 NCBI chr 6:29,060,221...29,073,876
Ensembl chr 6:29,060,220...29,073,877
JBrowse link
G Lepr leptin receptor multiple interactions
increases response to substance
EXP [LEPR gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL12B mRNA; [LEPR gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL18; [LEPR gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL18 mRNA; [LEPR gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL18 protein; [LEPR gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of SPP1 protein; Galactosamine promotes the reaction [LEPR gene mutant form results in increased expression of SPP1 mRNA]; Galactosamine promotes the reaction [LEPR gene mutant form results in increased expression of SPP1 protein]; SPP1 promotes the reaction [LEPR gene mutant form results in increased susceptibility to Galactosamine] CTD PMID:19913045 NCBI chr 4:101,717,137...101,815,352
Ensembl chr 4:101,717,404...101,815,352
JBrowse link
G Mapk1 mitogen-activated protein kinase 1 multiple interactions
increases phosphorylation
EXP
ISO
[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in decreased phosphorylation of MAPK1 protein; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of MAPK1 protein modified form; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of MAPK1 protein modified form; baicalein inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of MAPK1 protein modified form]; gentiopicroside inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of MAPK1 protein modified form]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of MAPK1 protein modified form]
Genistein inhibits the reaction [Galactosamine results in increased phosphorylation of MAPK1 protein]
CTD PMID:20558151 PMID:20850421 PMID:25620059 PMID:28887131 NCBI chr16:16,983,382...17,047,453
Ensembl chr16:16,983,382...17,047,453
JBrowse link
G Mapk3 mitogen-activated protein kinase 3 multiple interactions
increases phosphorylation
EXP
ISO
[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in decreased phosphorylation of MAPK3 protein; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of MAPK3 protein modified form; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of MAPK3 protein modified form; baicalein inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of MAPK3 protein modified form]; gentiopicroside inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of MAPK3 protein modified form]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of MAPK3 protein modified form]
Galactosamine results in increased phosphorylation of MAPK3 protein
Genistein inhibits the reaction [Galactosamine results in increased phosphorylation of MAPK3 protein]
CTD PMID:20558151 PMID:20850421 PMID:25620059 PMID:28887131 NCBI chr 7:126,759,626...126,765,816
Ensembl chr 7:126,759,601...126,765,819
JBrowse link
G Met met proto-oncogene multiple interactions EXP
ISO
[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of MET mRNA
4-phenylbutyric acid inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of MET mRNA]; [Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of MET mRNA
CTD PMID:28844859 PMID:28887131 NCBI chr 6:17,463,349...17,573,980
Ensembl chr 6:17,463,800...17,573,980
JBrowse link
G Mpo myeloperoxidase multiple interactions
increases activity
EXP
ISO
(2-(4-(4-isopropoxybenzyl)-phenylamino) imidazoline) inhibits the reaction [ONO 1301 inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of MPO protein]]; 2-chloro-5-nitrobenzanilide inhibits the reaction [geraniol inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased activity of MPO protein]]; [Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of MPO protein; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased activity of MPO protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased activity of MPO protein; beraprost inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of MPO protein]; geraniol inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased activity of MPO protein]; ONO 1301 inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of MPO protein]; S-allylcysteine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased activity of MPO protein]
Galactosamine results in increased activity of MPO protein
[Ascorbic Acid co-treated with beta Carotene co-treated with alpha-Tocopherol co-treated with Sodium Selenite] inhibits the reaction [Galactosamine results in increased activity of MPO protein]
CTD PMID:28887131 PMID:30550845 PMID:31022331 PMID:32453893 NCBI chr11:87,793,784...87,804,412
Ensembl chr11:87,793,581...87,804,413
JBrowse link
G Ndufb6 NADH:ubiquinone oxidoreductase subunit B6 multiple interactions
decreases expression
ISO Acetylcysteine inhibits the reaction [Galactosamine results in decreased expression of NDUFB6 mRNA]; coenzyme Q10 inhibits the reaction [Galactosamine results in decreased expression of NDUFB6 mRNA]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [Galactosamine results in decreased expression of NDUFB6 mRNA] CTD PMID:19523936 NCBI chr 4:40,270,591...40,279,421
Ensembl chr 4:40,270,591...40,279,421
JBrowse link
G Nfe2l2 nuclear factor, erythroid derived 2, like 2 affects localization
increases activity
multiple interactions
decreases expression
ISO
EXP
Galactosamine affects the localization of NFE2L2 protein
Galactosamine results in increased activity of NFE2L2 protein
[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of NFE2L2 mRNA; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of NFE2L2 mRNA; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of NFE2L2 protein; beraprost inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of NFE2L2 mRNA]; ONO 1301 inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of NFE2L2 mRNA]; Plant Extracts promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of NFE2L2 mRNA]; Plant Extracts promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of NFE2L2 protein]; Silymarin promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of NFE2L2 mRNA]; Silymarin promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of NFE2L2 protein]
mangiferin affects the reaction [Galactosamine affects the localization of NFE2L2 protein]; mangiferin inhibits the reaction [Galactosamine results in decreased expression of NFE2L2 protein]
CTD PMID:22310181 PMID:28887131 PMID:30114225 PMID:30203046 PMID:30236599 NCBI chr 2:75,675,513...75,704,663
Ensembl chr 2:75,675,513...75,704,641
JBrowse link
G Nfkb1 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 multiple interactions ISO alpha-Tocopherol inhibits the reaction [Galactosamine results in increased activity of [NFKB1 protein binds to NFKB1 protein]]; alpha-Tocopherol inhibits the reaction [Galactosamine results in increased activity of [RELA protein binds to NFKB1 protein]]; Galactosamine results in increased activity of [NFKB1 protein binds to NFKB1 protein]; Galactosamine results in increased activity of [RELA protein binds to NFKB1 protein] CTD PMID:17936189 NCBI chr 3:135,584,655...135,691,969
Ensembl chr 3:135,584,655...135,691,547
JBrowse link
G Nfkbia nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha multiple interactions
decreases expression
ISO
EXP
Alprostadil inhibits the reaction [Galactosamine results in decreased expression of NFKBIA protein]; Enzyme Inhibitors inhibits the reaction [Alprostadil inhibits the reaction [Galactosamine results in decreased expression of NFKBIA protein]]; mangiferin inhibits the reaction [Galactosamine results in decreased expression of NFKBIA protein]
[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of NFKBIA mRNA; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of NFKBIA protein modified form; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased phosphorylation of NFKBIA protein; [Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of NFKBIA protein; baicalein inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of NFKBIA protein]; geraniol inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of NFKBIA mRNA]; geraniol inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of NFKBIA protein modified form]; Glycyrrhetinic Acid inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased phosphorylation of NFKBIA protein]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of NFKBIA protein]
CTD PMID:15565661 PMID:20850421 PMID:22310181 PMID:28213090 PMID:30550845 NCBI chr12:55,489,409...55,492,647
Ensembl chr12:55,489,410...55,492,647
JBrowse link
G Nlrp3 NLR family, pyrin domain containing 3 multiple interactions EXP [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of NLRP3 protein; S-allylcysteine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of NLRP3 protein] CTD PMID:32453893 NCBI chr11:59,541,569...59,566,955
Ensembl chr11:59,541,568...59,566,956
JBrowse link
G Nos2 nitric oxide synthase 2, inducible multiple interactions
increases expression
EXP
ISO
[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of NOS2 mRNA; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of NOS2 protein; Indomethacin inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of NOS2 mRNA]; Indomethacin inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of NOS2 protein]; nimesulide inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of NOS2 mRNA]; nimesulide inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of NOS2 protein]
Galactosamine results in increased expression of NOS2 mRNA
alpha-Tocopherol inhibits the reaction [Galactosamine results in increased expression of NOS2 mRNA]
Galactosamine results in increased expression of NOS2 mRNA; Galactosamine results in increased expression of NOS2 promoter; Galactosamine results in increased expression of NOS2 protein
[[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of NOS2 mRNA] which results in increased chemical synthesis of Nitrites; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of NOS2 mRNA; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of NOS2 mRNA; Alprostadil inhibits the reaction [Galactosamine results in increased expression of NOS2 mRNA]; Alprostadil inhibits the reaction [Galactosamine results in increased expression of NOS2 promoter]; Alprostadil inhibits the reaction [Galactosamine results in increased expression of NOS2 protein]; Enzyme Inhibitors inhibits the reaction [Alprostadil inhibits the reaction [Galactosamine results in increased expression of NOS2 protein]]; Galactosamine promotes the reaction [Alprostadil results in increased expression of NOS2 protein]; Genistein inhibits the reaction [Galactosamine results in increased expression of NOS2 protein]; mangiferin inhibits the reaction [Galactosamine results in increased expression of NOS2 protein]; resveratrol inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of NOS2 mRNA]
CTD PMID:15189274 PMID:15565661 PMID:17936189 PMID:19796704 PMID:21401295 PMID:22107987 PMID:22118634 PMID:22310181 PMID:25620059 NCBI chr11:78,920,787...78,960,226
Ensembl chr11:78,920,787...78,960,254
JBrowse link
G Nqo1 NAD(P)H dehydrogenase, quinone 1 decreases expression
multiple interactions
ISO
EXP
Galactosamine results in decreased expression of NQO1 protein
[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of NQO1 mRNA
mangiferin inhibits the reaction [Galactosamine results in decreased expression of NQO1 protein]
CTD PMID:22310181 PMID:28887131 NCBI chr 8:107,388,225...107,403,205
Ensembl chr 8:107,388,225...107,403,206
JBrowse link
G Parp1 poly (ADP-ribose) polymerase family, member 1 multiple interactions EXP [[Galactosamine co-treated with Lipopolysaccharides] results in increased cleavage of and results in increased activity of CASP3 protein] which results in increased cleavage of PARP1 protein; gentiopicroside inhibits the reaction [[[Galactosamine co-treated with Lipopolysaccharides] results in increased cleavage of and results in increased activity of CASP3 protein] which results in increased cleavage of PARP1 protein] CTD PMID:20558151 NCBI chr 1:180,568,891...180,600,999
Ensembl chr 1:180,568,924...180,601,254
JBrowse link
G Ppara peroxisome proliferator activated receptor alpha increases expression
multiple interactions
increases activity
decreases expression
EXP
ISO
Galactosamine results in increased expression of PPARA mRNA
[Plant Extracts co-treated with Lipopolysaccharides co-treated with Galactosamine] results in increased expression of PPARA mRNA; [Plant Extracts co-treated with Lipopolysaccharides co-treated with Galactosamine] results in increased expression of PPARA protein; [Silymarin co-treated with Lipopolysaccharides co-treated with Galactosamine] results in increased expression of PPARA mRNA; [Silymarin co-treated with Lipopolysaccharides co-treated with Galactosamine] results in increased expression of PPARA protein
Galactosamine results in increased activity of PPARA protein
alpha-Tocopherol inhibits the reaction [Galactosamine results in decreased expression of PPARA mRNA]
CTD PMID:17936189 PMID:25689681 PMID:30203046 PMID:30236599 NCBI chr15:85,734,910...85,806,851
Ensembl chr15:85,734,983...85,802,819
JBrowse link
G Pparg peroxisome proliferator activated receptor gamma multiple interactions EXP [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in decreased expression of PPARG mRNA; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in decreased expression of PPARG protein; [Plant Extracts co-treated with Lipopolysaccharides co-treated with Galactosamine] results in increased expression of PPARG mRNA; [Plant Extracts co-treated with Lipopolysaccharides co-treated with Galactosamine] results in increased expression of PPARG protein; [Silymarin co-treated with Lipopolysaccharides co-treated with Galactosamine] results in increased expression of PPARG mRNA; [Silymarin co-treated with Lipopolysaccharides co-treated with Galactosamine] results in increased expression of PPARG protein; geraniol inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in decreased expression of PPARG mRNA]; geraniol inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in decreased expression of PPARG protein] CTD PMID:30236599 PMID:30550845 NCBI chr 6:115,360,879...115,490,404
Ensembl chr 6:115,360,951...115,490,399
JBrowse link
G Ppia peptidylprolyl isomerase A decreases expression ISO Galactosamine results in decreased expression of CYCA mRNA CTD PMID:22563491 NCBI chr11:6,415,867...6,419,817
Ensembl chr11:6,415,443...6,419,817
JBrowse link
G Ptgs1 prostaglandin-endoperoxide synthase 1 multiple interactions EXP [Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of PTGS1 mRNA; Indomethacin inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of PTGS1 mRNA]; nimesulide inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of PTGS1 mRNA] CTD PMID:22107987 NCBI chr 2:36,216,742...36,258,593
Ensembl chr 2:36,230,426...36,252,272
JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 multiple interactions
increases expression
EXP
ISO
[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of PTGS2 mRNA; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of PTGS2 protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of PTGS2 protein; Indomethacin inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of PTGS2 mRNA]; Indomethacin inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of PTGS2 protein]; nimesulide inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of PTGS2 mRNA]; nimesulide inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of PTGS2 protein]; S-allylcysteine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of PTGS2 protein]
Genistein inhibits the reaction [Galactosamine results in increased expression of PTGS2 protein]
CTD PMID:22107987 PMID:25620059 PMID:32453893 NCBI chr 1:150,100,031...150,108,234
Ensembl chr 1:150,100,031...150,108,227
JBrowse link
G Ptn pleiotrophin increases expression ISO Galactosamine results in increased expression of PTN mRNA; Galactosamine results in increased expression of PTN protein CTD PMID:12057922 NCBI chr 6:36,714,924...36,810,179
Ensembl chr 6:36,714,929...36,810,220
JBrowse link
G Pttg1 pituitary tumor-transforming gene 1 affects response to substance ISO PTTG1 mRNA affects the susceptibility to Galactosamine CTD PMID:19800905 NCBI chr11:43,420,244...43,427,463
Ensembl chr11:43,420,250...43,426,251
JBrowse link
G Rela v-rel reticuloendotheliosis viral oncogene homolog A (avian) multiple interactions
increases expression
EXP
ISO
[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of RELA mRNA; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of RELA protein modified form; [Lipopolysaccharides co-treated with Galactosamine] affects the localization of RELA protein; baicalein inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] affects the localization of RELA protein]; geraniol inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of RELA mRNA]; geraniol inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of RELA protein modified form]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] affects the localization of RELA protein]
alpha-Tocopherol inhibits the reaction [Galactosamine results in increased activity of [RELA protein binds to NFKB1 protein]]; Galactosamine results in increased activity of [RELA protein binds to NFKB1 protein]
mangiferin inhibits the reaction [Galactosamine results in increased expression of RELA protein]
CTD PMID:17936189 PMID:20850421 PMID:22310181 PMID:30550845 NCBI chr19:5,637,442...5,648,134
Ensembl chr19:5,637,483...5,648,130
JBrowse link
G Sdc3 syndecan 3 increases expression ISO Galactosamine results in increased expression of SDC3 mRNA CTD PMID:12057922 NCBI chr 4:130,792,537...130,826,318
Ensembl chr 4:130,792,537...130,826,319
JBrowse link
G Serpine1 serine (or cysteine) peptidase inhibitor, clade E, member 1 increases expression ISO Galactosamine results in increased expression of SERPINE1 mRNA CTD PMID:11779202 NCBI chr 5:137,061,504...137,072,272
Ensembl chr 5:137,061,504...137,072,268
JBrowse link
G Sesn2 sestrin 2 multiple interactions EXP [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of SESN2 mRNA; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of SESN2 protein CTD PMID:25637945 NCBI chr 4:132,492,804...132,510,456
Ensembl chr 4:132,492,032...132,510,501
JBrowse link
G Smad2 SMAD family member 2 increases phosphorylation
multiple interactions
ISO Galactosamine results in increased phosphorylation of SMAD2 protein
Genistein inhibits the reaction [Galactosamine results in increased phosphorylation of SMAD2 protein]
CTD PMID:27876602 NCBI chr18:76,241,090...76,311,748
Ensembl chr18:76,241,580...76,310,963
JBrowse link
G Smad3 SMAD family member 3 increases phosphorylation
multiple interactions
ISO Galactosamine results in increased phosphorylation of SMAD3 protein
Genistein inhibits the reaction [Galactosamine results in increased phosphorylation of SMAD3 protein]
CTD PMID:27876602 NCBI chr 9:63,646,766...63,757,994
Ensembl chr 9:63,646,767...63,757,994
JBrowse link
G Smad7 SMAD family member 7 decreases expression
multiple interactions
ISO Galactosamine results in decreased expression of SMAD7 protein
Genistein inhibits the reaction [Galactosamine results in decreased expression of SMAD7 protein]
CTD PMID:27876602 NCBI chr18:75,367,365...75,395,935
Ensembl chr18:75,367,529...75,395,935
JBrowse link
G Sod1 superoxide dismutase 1, soluble multiple interactions ISO [Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of SOD1 mRNA CTD PMID:21401295 NCBI chr16:90,220,762...90,226,333
Ensembl chr16:90,220,754...90,226,329
JBrowse link
G Sord sorbitol dehydrogenase multiple interactions EXP [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased activity of SORD protein; Dextromethorphan inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased activity of SORD protein] CTD PMID:30822415 NCBI chr 2:122,234,839...122,265,337
Ensembl chr 2:122,234,749...122,265,340
JBrowse link
G Spp1 secreted phosphoprotein 1 multiple interactions EXP [LEP gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of SPP1 protein; [LEPR gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of SPP1 protein; Galactosamine promotes the reaction [LEP gene mutant form results in increased expression of SPP1 mRNA]; Galactosamine promotes the reaction [LEP gene mutant form results in increased expression of SPP1 protein]; Galactosamine promotes the reaction [LEPR gene mutant form results in increased expression of SPP1 mRNA]; Galactosamine promotes the reaction [LEPR gene mutant form results in increased expression of SPP1 protein]; SPP1 promotes the reaction [LEP gene mutant form results in increased susceptibility to Galactosamine]; SPP1 promotes the reaction [LEPR gene mutant form results in increased susceptibility to Galactosamine] CTD PMID:19913045 NCBI chr 5:104,435,111...104,441,053
Ensembl chr 5:104,435,118...104,441,050
JBrowse link
G Stat3 signal transducer and activator of transcription 3 multiple interactions EXP [Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased phosphorylation of STAT3 protein; beraprost inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased phosphorylation of STAT3 protein]; ONO 1301 inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased phosphorylation of STAT3 protein] CTD PMID:28887131 NCBI chr11:100,886,806...100,939,594
Ensembl chr11:100,885,098...100,939,540
JBrowse link
G Stat5b signal transducer and activator of transcription 5B decreases activity EXP Galactosamine results in decreased activity of STAT5B protein CTD PMID:30114225 NCBI chr11:100,780,731...100,859,004
Ensembl chr11:100,780,731...100,850,724
JBrowse link
G Tgfb1 transforming growth factor, beta 1 multiple interactions
increases expression
ISO Genistein inhibits the reaction [Galactosamine results in increased expression of TGFB1 mRNA]; Genistein inhibits the reaction [Galactosamine results in increased expression of TGFB1 protein]; glycine propionyl carnitine inhibits the reaction [Galactosamine results in increased expression of TGFB1 protein]
Galactosamine results in increased expression of TGFB1 mRNA; Galactosamine results in increased expression of TGFB1 protein
CTD PMID:27836788 PMID:27876602 NCBI chr 7:25,687,002...25,705,077
Ensembl chr 7:25,687,002...25,705,077
JBrowse link
G Tlr4 toll-like receptor 4 multiple interactions EXP [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TLR4 protein; S-allylcysteine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TLR4 protein] CTD PMID:32453893 NCBI chr 4:66,827,551...66,846,581
Ensembl chr 4:66,827,584...66,930,284
JBrowse link
G Tnf tumor necrosis factor multiple interactions
increases expression
EXP
ISO
2-chloro-5-nitrobenzanilide inhibits the reaction [geraniol inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of TNF protein]]; 3-Hydroxybutyric Acid promotes the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of TNF protein]; [Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of TNF mRNA; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of TNF mRNA; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of TNF protein; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of TNF protein; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased expression of and results in increased secretion of TNF protein; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased expression of TNF mRNA; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased expression of TNF protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF mRNA; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF protein; [Methylene Chloride co-treated with Biliverdine] inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF protein]; [Nitric Oxide Donors results in increased abundance of Nitric Oxide] inhibits the reaction [[TNF protein co-treated with Galactosamine] results in increased activity of CASP3 protein]; [TNF protein co-treated with Galactosamine] results in increased activity of CASP3 protein; beraprost inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of TNF mRNA]; cobaltiprotoporphyrin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF mRNA]; cobaltiprotoporphyrin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF protein]; cobaltiprotoporphyrin inhibits the reaction [TNF protein promotes the reaction [Galactosamine results in increased activity of CASP3 protein]]; Dextromethorphan inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased expression of TNF protein]; Dithiothreitol inhibits the reaction [Nitric Oxide Donors inhibits the reaction [[TNF protein co-treated with Galactosamine] results in increased activity of CASP3 protein]]; gentiopicroside inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of TNF protein]; geraniol inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of TNF protein]; Glycyrrhetinic Acid inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased expression of and results in increased secretion of TNF protein]; Glycyrrhetinic Acid inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased expression of TNF mRNA]; hydroquinone metabolite inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF protein]; Indomethacin inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of TNF mRNA]; Melatonin inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of TNF protein]; nimesulide inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of TNF mRNA]; ONO 1301 inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of TNF mRNA]; Prednisolone inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF protein]; Rotenone inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of TNF mRNA]; Rotenone inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of TNF protein]; S-allylcysteine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF protein]; TNF protein promotes the reaction [Galactosamine results in increased activity of CASP3 protein]
Galactosamine results in increased expression of TNF mRNA; Galactosamine results in increased expression of TNF protein
[Galactosamine co-treated with TNF protein] results in increased activity of CASP3 protein; Galactosamine analog inhibits the reaction [TNF results in increased expression of ICAM1 protein]
[ALB protein co-treated with [Lipopolysaccharides co-treated with Galactosamine]] results in increased expression of TNF protein; Alprostadil promotes the reaction [Galactosamine results in increased expression of TNF protein]; Genistein inhibits the reaction [Galactosamine results in increased expression of TNF protein]; glycine propionyl carnitine inhibits the reaction [Galactosamine results in increased expression of TNF mRNA]; glycine propionyl carnitine inhibits the reaction [Galactosamine results in increased expression of TNF protein]; mangiferin inhibits the reaction [Galactosamine results in increased expression of TNF mRNA]; mangiferin inhibits the reaction [Galactosamine results in increased expression of TNF protein]
CTD PMID:9388267 PMID:10221824 PMID:11779202 PMID:14512878 PMID:15135310 PMID:15486963 PMID:16431966 PMID:17602819 PMID:17963606 PMID:20054000 PMID:20558151 PMID:22107987 PMID:22118634 PMID:22310181 PMID:24565947 PMID:24830863 PMID:25620059 PMID:26176423 PMID:27836788 PMID:28213090 PMID:28887131 PMID:30550845 PMID:30822415 PMID:31332890 PMID:32453893 NCBI chr17:35,199,367...35,202,007
Ensembl chr17:35,199,381...35,202,007
JBrowse link
G Traf6 TNF receptor-associated factor 6 multiple interactions EXP [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] promotes the reaction [TRAF6 protein binds to IRAK1 protein]; Glycyrrhetinic Acid inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] promotes the reaction [TRAF6 protein binds to IRAK1 protein]] CTD PMID:28213090 NCBI chr 2:101,678,420...101,701,668
Ensembl chr 2:101,678,429...101,701,669
JBrowse link
G Vegfa vascular endothelial growth factor A multiple interactions ISO 4-phenylbutyric acid inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of VEGFA mRNA]; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of VEGFA mRNA CTD PMID:28844859 NCBI chr17:46,016,993...46,032,377
Ensembl chr17:46,016,993...46,032,369
JBrowse link
G Xiap X-linked inhibitor of apoptosis multiple interactions EXP [Galactosamine co-treated with Lipopolysaccharides] results in decreased activity of XIAP protein; baicalein inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in decreased activity of XIAP protein]; Silymarin inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in decreased activity of XIAP protein] CTD PMID:20850421 NCBI chr  X:42,059,613...42,109,664
Ensembl chr  X:42,059,679...42,109,656
JBrowse link

Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 21549
    role 21527
      biological role 21525
        poison 18908
          toxin 14247
            2-amino-2-deoxy-D-galactopyranose 92
              alpha-D-galactosamine + 0
Path 2
Term Annotations click to browse term
  CHEBI ontology 21549
    subatomic particle 21534
      composite particle 21534
        hadron 21534
          baryon 21534
            nucleon 21534
              atomic nucleus 21534
                atom 21534
                  main group element atom 21437
                    p-block element atom 21437
                      carbon group element atom 21227
                        carbon atom 21124
                          organic molecular entity 21124
                            heteroorganic entity 20759
                              organochalcogen compound 19975
                                organooxygen compound 19899
                                  carbohydrates and carbohydrate derivatives 12810
                                    carbohydrate 12810
                                      carbohydrate derivative 12442
                                        amino sugar 1279
                                          amino monosaccharide 1274
                                            hexosamine 1274
                                              galactosamine 92
                                                D-galactosamine 92
                                                  2-amino-2-deoxy-D-galactopyranose 92
                                                    alpha-D-galactosamine + 0
paths to the root